Oral prolonged-release dienogest 2 mg and ethinylestradiol 0.02 mg in a 24/4-day regimen for polycystic ovary syndrome-associated hirsutism: a double-blind, randomised, placebo-controlled trial. [PDF]
Lobo R +7 more
europepmc +1 more source
Neuropeptide Y Promoter Variant rs16147 (-399 T/C) Is Associated With Susceptibility to Polycystic Ovary Syndrome. [PDF]
Yukcu F, Akcilar R, Biyik I, Sisman HI.
europepmc +1 more source
Case Report: Postmenopausal hyperandrogenism misled by adrenal incidentaloma: a rare case of androgen-secreting ovarian adult granulosa cell tumor and clinical implications. [PDF]
Cao C, Wang X.
europepmc +1 more source
R. S. Sawers, V. A. Randall, M. J. Iqbal
openaire +1 more source
Development of a case definition for polycystic ovary syndrome using administrative health data: a validation study. [PDF]
Salem JN +9 more
europepmc +1 more source
Obstetrics and gynecology-epitomes of progress: a new and effective treatment of hirsutism.
F W Hanson
openalex +1 more source
Patient characteristics associated with symptoms of anxiety, depression, and reduced body appreciation in women with polycystic ovary syndrome. [PDF]
Jannink TI +5 more
europepmc +1 more source
Prenatal Androgenization of Ewes as a Model of Hirsutism in Polycystic Ovary Syndrome [PDF]
Joabel Tonellotto dos Santos +11 more
openalex +1 more source
Assessment of body composition, quality of life, and depression in women with polycystic ovary syndrome. [PDF]
Ponce T +3 more
europepmc +1 more source

